<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31231374</PMID><DateCompleted><Year>2020</Year><Month>07</Month><Day>20</Day></DateCompleted><DateRevised><Year>2020</Year><Month>07</Month><Day>20</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><PubDate><Year>2019</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>Increased CD14<sup>+</sup>HLA-DR<sup>-/low</sup> Myeloid-Derived Suppressor Cells Correlate With Disease Severity in Systemic Lupus Erythematosus Patients in an iNOS-Dependent Manner.</ArticleTitle><Pagination><StartPage>1202</StartPage><MedlinePgn>1202</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1202</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2019.01202</ELocationID><Abstract><AbstractText>Myeloid-derived suppressor cells (MDSCs) comprise of a population of cells, which suppress the innate and adaptive immune system via different mechanisms. MDSCs are accumulated under pathological conditions. The present study aimed to clarify the pathological role of MDSCs in systemic lupus erythematosus (SLE) patients. Consequently, the level of circulating M-MDSCs was significantly increased in newly diagnosed SLE patients as compared to healthy controls. An elevated level of M-MDSCs was positively correlated with the disease severity in SLE patients and an immunosuppressive role was exerted in an iNOS-dependent manner. The decrease in the number of M-MDSCs after therapy rendered them as an indicator for the efficacy of treatment. These results demonstrated that M-MDSCs participated in the pathological progress in SLE patients. Thus, MDSCs are attractive biomarkers and therapeutic targets for SLE patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Zhitao</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Hematology, The Second Affiliated Hospital of Anhui Medical University, Hefei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Fengfeng</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Hematology, The Second Affiliated Hospital of Anhui Medical University, Hefei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jiyu</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Hematology, The Second Affiliated Hospital of Anhui Medical University, Hefei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tao</LastName><ForeName>Qianshan</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, The Second Affiliated Hospital of Anhui Medical University, Hefei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Xuanxuan</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, The Second Affiliated Hospital of Anhui Medical University, Hefei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Huiping</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Hematology, The Second Affiliated Hospital of Anhui Medical University, Hefei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiong</LastName><ForeName>Shudao</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Hematology, The Second Affiliated Hospital of Anhui Medical University, Hefei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yiping</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Centre for Transplantation and Renal Research, Westmead Millennium Institute, The University of Sydney, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhai</LastName><ForeName>Zhimin</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Hematology, The Second Affiliated Hospital of Anhui Medical University, Hefei, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>05</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000632510">CD14 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006684">HLA-DR Antigens</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018950">Lipopolysaccharide Receptors</NameOfSubstance></Chemical><Chemical><RegistryNumber>82115-62-6</RegistryNumber><NameOfSubstance UI="D007371">Interferon-gamma</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.14.13.39</RegistryNumber><NameOfSubstance UI="C496319">NOS2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.14.13.39</RegistryNumber><NameOfSubstance UI="D052247">Nitric Oxide Synthase Type II</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015496" MajorTopicYN="N">CD4-Positive T-Lymphocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006684" MajorTopicYN="N">HLA-DR Antigens</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007108" MajorTopicYN="N">Immune Tolerance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007371" MajorTopicYN="N">Interferon-gamma</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007963" MajorTopicYN="N">Leukocytes, Mononuclear</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018950" MajorTopicYN="N">Lipopolysaccharide Receptors</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="N">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072737" MajorTopicYN="N">Myeloid-Derived Suppressor Cells</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D052247" MajorTopicYN="N">Nitric Oxide Synthase Type II</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SLE</Keyword><Keyword MajorTopicYN="N">disease severity</Keyword><Keyword MajorTopicYN="N">iNOS</Keyword><Keyword MajorTopicYN="N">immunosuppression</Keyword><Keyword MajorTopicYN="N">myeloid-derived suppressor cells</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>1</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>5</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>6</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>6</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>7</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31231374</ArticleId><ArticleId IdType="pmc">PMC6558381</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2019.01202</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Tsokos GC. Systemic lupus erythematosus. N Engl J Med. (2011) 365:2110&#x2013;21. 10.1056/NEJMra1100359</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1100359</ArticleId><ArticleId IdType="pubmed">22129255</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahren-Herlenius M, Dorner T. Immunopathogenic mechanisms of systemic autoimmune disease. Lancet. (2013) 382:819&#x2013;31. 10.1016/S0140-6736(13)60954-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(13)60954-X</ArticleId><ArticleId IdType="pubmed">23993191</ArticleId></ArticleIdList></Reference><Reference><Citation>Pyzer AR, Cole L, Rosenblatt J, Avigan DE. Myeloid-derived suppressor cells as effectors of immune suppression in cancer. Int J Cancer. (2016) 139:1915&#x2013;26. 10.1002/ijc.30232</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ijc.30232</ArticleId><ArticleId IdType="pubmed">27299510</ArticleId></ArticleIdList></Reference><Reference><Citation>Marvel D, Gabrilovich DI. Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected. J Clin Invest. (2015) 125:3356&#x2013;64. 10.1172/JCI80005</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI80005</ArticleId><ArticleId IdType="pmc">PMC4588239</ArticleId><ArticleId IdType="pubmed">26168215</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei C, Wang Y, Ma L, Wang X, Chi H, Zhang S, et al. . Rapamycin nano-micelle ophthalmic solution reduces corneal allograft rejection by potentiating myeloid-derived suppressor cells' function. Front Immunol. (2018) 9:2283. 10.3389/fimmu.2018.02283</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.02283</ArticleId><ArticleId IdType="pmc">PMC6186809</ArticleId><ArticleId IdType="pubmed">30349533</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang CJ, Yang YH, Chiu CJ, Lu LC, Liao CC, Liang CW, et al. . Targeting tumor-infiltrating Ly6G(+) myeloid cells improves sorafenib efficacy in mouse orthotopic hepatocellular carcinoma. Int J Cancer. (2018) 142:1878&#x2013;89. 10.1002/ijc.31216</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ijc.31216</ArticleId><ArticleId IdType="pubmed">29266245</ArticleId></ArticleIdList></Reference><Reference><Citation>Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. (2009) 9:162&#x2013;74. 10.1038/nri2506</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri2506</ArticleId><ArticleId IdType="pmc">PMC2828349</ArticleId><ArticleId IdType="pubmed">19197294</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsiganov EN, Verbina EM, Radaeva TV, Sosunov VV, Kosmiadi GA, Nikitina IY, et al. Gr-1dimCD11b+ immature myeloid-derived suppressor cells but not neutrophils are markers of lethal tuberculosis infection in mice. J Immunol. (2014) 192:4718&#x2013;27. 10.4049/jimmunol.1301365</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1301365</ArticleId><ArticleId IdType="pmc">PMC4537794</ArticleId><ArticleId IdType="pubmed">24711621</ArticleId></ArticleIdList></Reference><Reference><Citation>Manjili MH. Phenotypic plasticity of MDSC in cancers. Immunol Invest. (2012) 41:711&#x2013;21. 10.3109/08820139.2012.673670</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/08820139.2012.673670</ArticleId><ArticleId IdType="pubmed">23017142</ArticleId></ArticleIdList></Reference><Reference><Citation>Greten TF, Manns MP, Korangy F. Myeloid derived suppressor cells in human diseases. Int Immunopharmacol. (2011) 11:802&#x2013;7. 10.1016/j.intimp.2011.01.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2011.01.003</ArticleId><ArticleId IdType="pmc">PMC3478130</ArticleId><ArticleId IdType="pubmed">21237299</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao F, Hoechst B, Duffy A, Gamrekelashvili J, Fioravanti S, Manns MP, et al. . S100A9 a new marker for monocytic human myeloid-derived suppressor cells. Immunology. (2012) 136:176&#x2013;83. 10.1111/j.1365-2567.2012.03566.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2567.2012.03566.x</ArticleId><ArticleId IdType="pmc">PMC3403264</ArticleId><ArticleId IdType="pubmed">22304731</ArticleId></ArticleIdList></Reference><Reference><Citation>Talmadge JE, Gabrilovich DI. History of myeloid-derived suppressor cells. Nat Rev Cancer. (2013) 13:739&#x2013;52. 10.1038/nrc3581</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrc3581</ArticleId><ArticleId IdType="pmc">PMC4358792</ArticleId><ArticleId IdType="pubmed">24060865</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohl K, Tenbrock K. Reactive oxygen species as regulators of MDSC-mediated immune suppression. Front Immunol. (2018) 9:2499. 10.3389/fimmu.2018.02499</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.02499</ArticleId><ArticleId IdType="pmc">PMC6218613</ArticleId><ArticleId IdType="pubmed">30425715</ArticleId></ArticleIdList></Reference><Reference><Citation>Lechner MG, Liebertz DJ, Epstein AL. Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells. J Immunol. (2010) 185:2273&#x2013;84. 10.4049/jimmunol.1000901</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1000901</ArticleId><ArticleId IdType="pmc">PMC2923483</ArticleId><ArticleId IdType="pubmed">20644162</ArticleId></ArticleIdList></Reference><Reference><Citation>Li M, Zhu D, Wang T, Xia X, Tian J, Wang S. Roles of myeloid-derived suppressor cell subpopulations in autoimmune arthritis. Front Immunol. (2018) 9:2849. 10.3389/fimmu.2018.02849</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.02849</ArticleId><ArticleId IdType="pmc">PMC6288996</ArticleId><ArticleId IdType="pubmed">30564242</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujii W, Ashihara E, Hirai H, Nagahara H, Kajitani N, Fujioka K, et al. . Myeloid-derived suppressor cells play crucial roles in the regulation of mouse collagen-induced arthritis. J Immunol. (2013) 191:1073&#x2013;81. 10.4049/jimmunol.1203535</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1203535</ArticleId><ArticleId IdType="pubmed">23804709</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin B, Ma G, Yen CY, Zhou Z, Wang GX, Divino CM, et al. . Myeloid-derived suppressor cells prevent type 1 diabetes in murine models. J Immunol. (2010) 185:5828&#x2013;34. 10.4049/jimmunol.0903636</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.0903636</ArticleId><ArticleId IdType="pmc">PMC4355963</ArticleId><ArticleId IdType="pubmed">20956337</ArticleId></ArticleIdList></Reference><Reference><Citation>Guan Q, Moreno S, Qing G, Weiss CR, Lu L, Bernstein CN, et al. . The role and potential therapeutic application of myeloid-derived suppressor cells in TNBS-induced colitis. J Leukoc Biol. (2013) 94:803&#x2013;11. 10.1189/jlb.0113050</Citation><ArticleIdList><ArticleId IdType="doi">10.1189/jlb.0113050</ArticleId><ArticleId IdType="pubmed">23901119</ArticleId></ArticleIdList></Reference><Reference><Citation>Ioannou M, Alissafi T, Lazaridis I, Deraos G, Matsoukas J, Gravanis A, et al. . Crucial role of granulocytic myeloid-derived suppressor cells in the regulation of central nervous system autoimmune disease. J Immunol. (2012) 188:1136&#x2013;46. 10.4049/jimmunol.1101816</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1101816</ArticleId><ArticleId IdType="pubmed">22210912</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwata Y, Furuichi K, Kitagawa K, Hara A, Okumura T, Kokubo S, et al. . Involvement of CD11b+ GR-1 low cells in autoimmune disorder in MRL-Fas lpr mouse. Clin Exp Nephrol. (2010) 14:411&#x2013;7. 10.1007/s10157-010-0309-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10157-010-0309-9</ArticleId><ArticleId IdType="pubmed">20652350</ArticleId></ArticleIdList></Reference><Reference><Citation>Trigunaite A, Khan A, Der E, Song A, Varikuti S, Jorgensen TN. Gr-1(high) CD11b+ cells suppress B cell differentiation and lupus-like disease in lupus-prone male mice. Arthritis Rheum. (2013) 65:2392&#x2013;402. 10.1002/art.38048</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.38048</ArticleId><ArticleId IdType="pubmed">23754362</ArticleId></ArticleIdList></Reference><Reference><Citation>Der E, Dimo J, Trigunaite A, Jones J, Jorgensen TN. Gr1+ cells suppress T-dependent antibody responses in (NZB x NZW)F1 male mice through inhibition of T follicular helper cells and germinal center formation. J Immunol. (2014) 192:1570&#x2013;6. 10.4049/jimmunol.1302479</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1302479</ArticleId><ArticleId IdType="pubmed">24442428</ArticleId></ArticleIdList></Reference><Reference><Citation>Vlachou K, Mintzas K, Glymenaki M, Ioannou M, Papadaki G, Bertsias GK, et al. . Elimination of granulocytic myeloid-derived suppressor cells in lupus-prone mice linked to reactive oxygen species-dependent extracellular trap formation. Arthritis Rheumatol. (2016) 68:449&#x2013;61. 10.1002/art.39441</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.39441</ArticleId><ArticleId IdType="pubmed">26414650</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu H, Zhen Y, Ma Z, Li H, Yu J, Xu ZG, et al. . Arginase-1-dependent promotion of TH17 differentiation and disease progression by MDSCs in systemic lupus erythematosus. Sci Transl Med. (2016) 8:331ra40. 10.1126/scitranslmed.aae0482</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aae0482</ArticleId><ArticleId IdType="pmc">PMC4895207</ArticleId><ArticleId IdType="pubmed">27009269</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. . The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. (1982) 25:1271&#x2013;7. 10.1002/art.1780251101</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780251101</ArticleId><ArticleId IdType="pubmed">7138600</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri M. Disease activity assessment in SLE: do we have the right instruments? Ann Rheum Dis. (2007) 66 (Suppl. 3):iii61&#x2013;4. 10.1136/ard.2007.078477</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2007.078477</ArticleId><ArticleId IdType="pmc">PMC2095289</ArticleId><ArticleId IdType="pubmed">17934099</ArticleId></ArticleIdList></Reference><Reference><Citation>Bayne LJ, Beatty GL, Jhala N, Clark CE, Rhim AD, Stanger BZ, et al. . Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. Cancer Cell. (2012) 21:822&#x2013;35. 10.1016/j.ccr.2012.04.025</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccr.2012.04.025</ArticleId><ArticleId IdType="pmc">PMC3575028</ArticleId><ArticleId IdType="pubmed">22698406</ArticleId></ArticleIdList></Reference><Reference><Citation>Haverkamp JM, Smith AM, Weinlich R, Dillon CP, Qualls JE, Neale G, et al. . Myeloid-derived suppressor activity is mediated by monocytic lineages maintained by continuous inhibition of extrinsic and intrinsic death pathways. Immunity. (2014) 41:947&#x2013;59. 10.1016/j.immuni.2014.10.020</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2014.10.020</ArticleId><ArticleId IdType="pmc">PMC4272664</ArticleId><ArticleId IdType="pubmed">25500368</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar V, Patel S, Tcyganov E, Gabrilovich DI. The nature of myeloid-derived suppressor cells in the tumor microenvironment. Trends Immunol. (2016) 37:208&#x2013;20. 10.1016/j.it.2016.01.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.it.2016.01.004</ArticleId><ArticleId IdType="pmc">PMC4775398</ArticleId><ArticleId IdType="pubmed">26858199</ArticleId></ArticleIdList></Reference><Reference><Citation>Crook KR, Liu P. Role of myeloid-derived suppressor cells in autoimmune disease. World J Immunol. (2014) 4:26&#x2013;33. 10.5411/wji.v4.i1.26</Citation><ArticleIdList><ArticleId IdType="doi">10.5411/wji.v4.i1.26</ArticleId><ArticleId IdType="pmc">PMC4302755</ArticleId><ArticleId IdType="pubmed">25621222</ArticleId></ArticleIdList></Reference><Reference><Citation>Crook KR, Jin M, Weeks MF, Rampersad RR, Baldi RM, Glekas AS, et al. . Myeloid-derived suppressor cells regulate T cell and B cell responses during autoimmune disease. J Leukoc Biol. (2015) 97:573&#x2013;82. 10.1189/jlb.4A0314-139R</Citation><ArticleIdList><ArticleId IdType="doi">10.1189/jlb.4A0314-139R</ArticleId><ArticleId IdType="pmc">PMC4338846</ArticleId><ArticleId IdType="pubmed">25583578</ArticleId></ArticleIdList></Reference><Reference><Citation>Bronte V, Brandau S, Chen SH, Colombo MP, Frey AB, Greten TF, et al. . Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun. (2016) 7:12150. 10.1038/ncomms12150</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms12150</ArticleId><ArticleId IdType="pmc">PMC4935811</ArticleId><ArticleId IdType="pubmed">27381735</ArticleId></ArticleIdList></Reference><Reference><Citation>Umansky V, Blattner C, Fleming V, Hu X, Gebhardt C, Altevogt P, et al. . Myeloid-derived suppressor cells and tumor escape from immune surveillance. Semin Immunopathol. (2016) 39:295&#x2013;305. 10.1007/s00281-016-0597-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00281-016-0597-6</ArticleId><ArticleId IdType="pubmed">27787613</ArticleId></ArticleIdList></Reference><Reference><Citation>Umansky V, Blattner C, Gebhardt C, Utikal J. The role of myeloid-derived suppressor cells (MDSC) in cancer progression. Vaccines. (2016) 4:E36. 10.3390/vaccines4040036</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines4040036</ArticleId><ArticleId IdType="pmc">PMC5192356</ArticleId><ArticleId IdType="pubmed">27827871</ArticleId></ArticleIdList></Reference><Reference><Citation>Motallebnezhad M, Jadidi-Niaragh F, Qamsari ES, Bagheri S, Gharibi T, Yousefi M. The immunobiology of myeloid-derived suppressor cells in cancer. Tumour Biol. (2016) 37:1387&#x2013;406. 10.1007/s13277-015-4477-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13277-015-4477-9</ArticleId><ArticleId IdType="pubmed">26611648</ArticleId></ArticleIdList></Reference><Reference><Citation>Rastad JL, Green WR. Myeloid-derived suppressor cells in murine AIDS inhibit B-cell responses in part via soluble mediators including reactive oxygen and nitrogen species, and TGF-beta. Virology. (2016) 499:9&#x2013;22. 10.1016/j.virol.2016.08.031</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2016.08.031</ArticleId><ArticleId IdType="pmc">PMC5102787</ArticleId><ArticleId IdType="pubmed">27632561</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorgun GT, Whitehill G, Anderson JL, Hideshima T, Maguire C, Laubach J, et al. . Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans. Blood. (2013) 121:2975&#x2013;87. 10.1182/blood-2012-08-448548</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2012-08-448548</ArticleId><ArticleId IdType="pmc">PMC3624943</ArticleId><ArticleId IdType="pubmed">23321256</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu CT, Hsieh CC, Lin CC, Chen WC, Hong JH, Chen MF. Significance of IL-6 in the transition of hormone-resistant prostate cancer and the induction of myeloid-derived suppressor cells. J Mol Med. (2012) 90:1343&#x2013;55. 10.1007/s00109-012-0916-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00109-012-0916-x</ArticleId><ArticleId IdType="pubmed">22660275</ArticleId></ArticleIdList></Reference><Reference><Citation>Schafer ZT, Brugge JS. IL-6 involvement in epithelial cancers. J Clin Invest. (2007) 117:3660&#x2013;3. 10.1172/JCI34237</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI34237</ArticleId><ArticleId IdType="pmc">PMC2096452</ArticleId><ArticleId IdType="pubmed">18060028</ArticleId></ArticleIdList></Reference><Reference><Citation>Casella G, Finardi A, Descamps H, Colombo F, Maiorino C, Ruffini F, et al. IL-27, but not IL-35, inhibits neuroinflammation through modulating GM-CSF expression. Sci Rep. (2017) 7:16547 10.1038/s41598-017-16702-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-16702-w</ArticleId><ArticleId IdType="pmc">PMC5707351</ArticleId><ArticleId IdType="pubmed">29185463</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo C, Hu F, Yi H, Feng Z, Li C, Shi L, et al. . Myeloid-derived suppressor cells have a proinflammatory role in the pathogenesis of autoimmune arthritis. Ann Rheum Dis. (2016) 75:278&#x2013;85. 10.1136/annrheumdis-2014-205508</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2014-205508</ArticleId><ArticleId IdType="pmc">PMC4418961</ArticleId><ArticleId IdType="pubmed">25371442</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>